(Rac) -NSC305787

NSC305787 is an inhibitor of ezrin with a Kd of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC50 of 8.3 μM, has antitumor activity.

Product Specifications

CAS Number

[785718-37-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Arp2/3 Complex

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NSC305787.html

Purity

99.29

Solubility

DMSO : 6 mg/mL (ultrasonic; warming)

Smiles

OC(C1CCCCN1)C2=CC(C3(C[C@H](C4)C5)C[C@H]5C[C@H]4C3)=NC(C(Cl)=C6)=C2C=C6Cl

Molecular Formula

C25H30Cl2N2O

Molecular Weight

445.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Bulut G, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012 Jan 19;31 (3) :269-81.|[2]Çelik H, et al. Ezrin Inhibition Up-regulates Stress Response Gene Expression. J Biol Chem. 2016 Jun 17;291 (25) :13257-70.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Am J Physiol Renal Physiol. 2025 Aug 1;329 (2) :F269-F283.|Biochem Biophys Res Commun. 2024 Apr 9:703:149685.|Cell. 2023 Jan 5;186 (1) :112-130.e20.|Front Cell Dev Biol. 2021 Sep 3;9:663207.|Life Sci. 2020 Aug 1;254:117681.|PLoS Pathog. 2019 May 9;15 (5) :e1007737.|J Cell Mol Med. 2022 Apr;26 (7) :2089-2103.|Sci Adv. 2025 Oct 24;11 (43) :eads9181.